IN Placebo

OTHER2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID), FluGen Inc

Conditions

InfluenzaInfluenza Vaccine

Phase 1

Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine

CompletedNCT05027932

National Institute of Allergy and Infectious Diseases (NIAID)Influenza

Start: 2022-06-27End: 2025-02-25Updated: 2025-04-08

Safety and Immunogenicity of Cam2020 M2SR H3N2 Monovalent Influenza Vaccine Alone or With Licensed IIV in Older Adults

CompletedNCT05163847

FluGen IncInfluenza Vaccine

Start: 2022-06-14End: 2022-11-03Updated: 2022-11-14

Related Papers

Safety and immunogenicity of the intranasal H3N2 M2-deficient single-replication influenza vaccine alone or coadministered with an inactivated influenza vaccine (Fluzone High-Dose Quadrivalent) in adults aged 65-85 years in the USA: a multicentre, randomised, double-blind, double-dummy, phase 1b trial.

2024-07-118 citations

1155. Coadministration of Intranasal M2SR (M2-deficient Single Replication) Investigational Influenza Vaccine with Fluzone High Dose Induces Superior Immune Responses to Fluzone High Dose Alone in 65-85 Year Old Adults

Open Forum Infectious Diseases2023-11-27